After Viking Therapeutics (VKTX) announced the initiation of their two randomized, double-blind, placebo-controlled, Phase 3 VANQUISH obesity studies with VK2735, BTIG analyst Justin Zelin said the firm is “encouraged” by Viking’s execution and progress across their obesity franchise. The firm, which continues to see “tremendous value in the company’s potentially best-in-class portfolio of obesity and metabolic disease programs,” reiterates a Buy rating and $125 price target on Viking shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics’ VK2735: A Promising Disruptor in the Obesity Market with Strategic Phase III Trials and Market Appeal
- Viking Therapeutics: Buy Rating Affirmed on Promising VK2735 Trials and Strategic Developments
- Viking Therapeutics initiates Vanquish Phase 3 clinical program for VK2735
- Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%
- Viking Therapeutics management to meet with B. Riley